AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares AbCellera Biologics and Cytokinetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
| Cytokinetics | -686.63% | N/A | -48.26% |
Risk and Volatility
AbCellera Biologics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Insider and Institutional Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares AbCellera Biologics and Cytokinetics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbCellera Biologics | $67.85 million | 54.00 | -$146.41 million | ($0.48) | -24.90 |
| Cytokinetics | $113.29 million | 71.97 | -$784.96 million | ($6.04) | -9.69 |
AbCellera Biologics has higher earnings, but lower revenue than Cytokinetics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for AbCellera Biologics and Cytokinetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 6 | 2 | 2.90 |
| Cytokinetics | 1 | 1 | 19 | 0 | 2.86 |
AbCellera Biologics presently has a consensus target price of $16.33, indicating a potential upside of 36.68%. Cytokinetics has a consensus target price of $106.67, indicating a potential upside of 82.24%. Given Cytokinetics’ higher possible upside, analysts clearly believe Cytokinetics is more favorable than AbCellera Biologics.
Summary
AbCellera Biologics beats Cytokinetics on 9 of the 15 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
